Author Archive: David Thomas, CFA

David Thomas, CFA

David is currently Director of Industry Research and Analysis at BIO in Washington, DC. In this role, he is responsible for financial statistics and analysis of the biotechnology sector and contributes to BIO’s policy activities as well as programming for BIO’s investor conferences. Prior to joining BIO, he was a research scientist at the J. Craig Venter Institute working on the “synthetic cell” team led by Nobel Laureate Hamilton Smith. Before his role in synthetic biology, David worked as a scientist in drug discovery at Amgen, Millennium, and Novartis. His scientific expertise is in protein engineering, enzymology, and synthetic biology. David has earned the Chartered Financial Analyst (CFA) designation and holds a master’s degree in biochemistry.

Latest Posts

Results from the BIO Convention 2013 Meeting Analysis of Therapeutic In/Out Licensors

BIO’s results from the BIO 2013 Convention 1×1 meeting analysis conducted to identify trends and intentions of therapeutic in-licensors and out-licensors were released today. The analysis looked at the meeting activity of 180 in-licensors attending the Chicago conference in terms of what therapeutic areas and stages of development were in highest demand. Of the 804 drug R&D companies, companies in Phase I/Rare Disease came out ahead as a group, with an average of >17 meetings/company. This was followed by Phase Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , ,

The IPO Road Less Traveled: Form 10

When investors talk about alternate exits for private companies beyond the traditional IPO they are usually referring to reverse mergers, if not outright acquisitions. However, another route is gaining some traction with sophisticated biotech investors – the so-called Form-10 pathway. Although it can be used in combination with reverse mergers, recent SEC rules applied to reverse mergers have shifted interest towards a more direct Form-10 approach to public markets. At last week’s BIO CEO & Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post

Biobuck M&A in Full Gear

Graph

The 2012 M&A results are in and trends are mixed. Last year was a down year in terms of total acquisitions and total dollar value amounts vs 2011.  What was not down however was the earnout structures embedded in these deals. More and more M&A transactions are looking like partnering deals structured with CVRs accounting for the bolus of the reported purchase price. Here is a look at therapeutic-focused acquisitions (valued at >$10M) over the Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

A Big Year for Novel Drugs Approvals

What was your top Biopharma highlight for 2012? If it wasn’t the stellar move in the AMEX Biotech Index (up 42%), or the reauthorization of PDUFA, then perhaps it was the decade high for innovative drugs approvals. We would need to go back to the 1990s to find a year with as many FDA approvals for novel drugs as we had in 2012. Adding to the positive trend in numbers, up 29% from the robust Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post

Small Companies, Big Returns

The broader biotech indices are up more than 30 percent this year and have reached levels not seen since the peak of March 2000. Larger biotechs account for much of the index returns, as we have described previously, and have helped the sector outperform the S&P 500 by two fold. But how have smaller biotech companies been performing? As of Nov 30, 27 companies that started the year under $1 billion in market capitalization have Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , ,